WO2003080617A8 - Pyrazolopyrimidine derivatives - Google Patents

Pyrazolopyrimidine derivatives

Info

Publication number
WO2003080617A8
WO2003080617A8 PCT/EP2003/003196 EP0303196W WO03080617A8 WO 2003080617 A8 WO2003080617 A8 WO 2003080617A8 EP 0303196 W EP0303196 W EP 0303196W WO 03080617 A8 WO03080617 A8 WO 03080617A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pyrazolopyrimidine derivatives
pyrazolopyrimidine
derivatives
gsk
Prior art date
Application number
PCT/EP2003/003196
Other languages
French (fr)
Other versions
WO2003080617A1 (en
Inventor
Jason Witherington
Original Assignee
Glaxo Group Ltd
Jason Witherington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Jason Witherington filed Critical Glaxo Group Ltd
Priority to AU2003226725A priority Critical patent/AU2003226725A1/en
Publication of WO2003080617A1 publication Critical patent/WO2003080617A1/en
Publication of WO2003080617A8 publication Critical patent/WO2003080617A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

A compound of formula (I),or a salt thereof, or a solvate thereof, wherein, R1, R2 and R3 are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds or the manufacture of a medicament for the treatment of conditions associated with a need for the inhibition of GSK-3. .
PCT/EP2003/003196 2002-03-27 2003-03-25 Pyrazolopyrimidine derivatives WO2003080617A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003226725A AU2003226725A1 (en) 2002-03-27 2003-03-25 Pyrazolopyrimidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207246.0A GB0207246D0 (en) 2002-03-27 2002-03-27 Novel compounds
GB0207246.0 2002-03-27

Publications (2)

Publication Number Publication Date
WO2003080617A1 WO2003080617A1 (en) 2003-10-02
WO2003080617A8 true WO2003080617A8 (en) 2003-11-13

Family

ID=9933830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003196 WO2003080617A1 (en) 2002-03-27 2003-03-25 Pyrazolopyrimidine derivatives

Country Status (3)

Country Link
AU (1) AU2003226725A1 (en)
GB (1) GB0207246D0 (en)
WO (1) WO2003080617A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Regulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CA2637530A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
WO2001081345A1 (en) * 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Aromatic amide compounds
AU2001287898A1 (en) * 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics
JP2004518662A (en) * 2000-12-19 2004-06-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Pyrazolo [3,4-C] pyridines as GSK-3 inhibitors
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI

Also Published As

Publication number Publication date
AU2003226725A8 (en) 2003-10-08
AU2003226725A1 (en) 2003-10-08
GB0207246D0 (en) 2002-05-08
WO2003080617A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
ATE450533T1 (en) CARBOXAMIDE DERIVATIVES
GB0119249D0 (en) Organic compounds
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2005021519A3 (en) 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
WO2006005609A3 (en) Substituted oxindol derivatives and medicaments containing the same
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2004101528A3 (en) Isoquinoline derivatives and their use as gfat inhibitors
WO2005051302A3 (en) Bicyclic inhibitors of mek and methods of use thereof
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
TW200615266A (en) Organic compounds
WO2004039753A3 (en) Phenyl compounds
WO2005044192A3 (en) Triazole compounds and uses related thereto
TW200502230A (en) Dual nk1/nk3 derivatives
NO20055766L (en) Positive modulators of nicotine acetylcholine receptors
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
GB0109122D0 (en) Novel compounds
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
TW200639156A (en) New compounds
DE602004011966D1 (en) Heterocyclylverbindungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP